ZURICH, Switzerland, November 4, 2011 /PRNewswire/ -- Major milestone achieved in the commercial launch of new technology in the treatment of patients with refractory ascites

In the first large study to affirm wider cancer-fighting applications for Zometa and other bone-building drugs called bisphosphonates, new research has found that Zometa, a bone loss prevention drug used by women undergoing breast cancer treatment, substantially reduced the risk of breast cancer recurrence.

By Bonderman, Diana; Nowotny, Regina; Skoro-Sajer, Nika; Jakowitsch, Johannes; Et al Background: Bosentan, an oral endothelin (ET)-A/ET-B receptor antagonist, is effective in the treatment of pulmonary arterial hypertension.

Cytochrome P-450 (CYP) genes encode for membrane-bound, heme- containing enzymes that catalyze the oxidation of various drugs and endogenous substrates such as vitamin D, steroids, or fatty acids, including arachidonic acid (AA).